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Abstract
Aim Cervical cancer incidence and mortality have de-
creased for the last 20 years in Austria; however, they
remain relatively high in comparison to other European
countries. Screening quality has been suboptimal. In this
paper we aim to predict the population-wide long-term
effects on cervical cancer morbidity and mortality after
introducing an HPV vaccination for 12-year-old girls (and
boys) in addition to current screening in comparison with
screening only.
Methods Health effects are predicted by a dynamic trans-
mission model that was previously applied in the UK and
the Norwegian contexts and validated for Austria. Out-
comes analyzed are restricted to cervical cancer mortality
and morbidity, which are predicted until 2060 assuming a
coverage rate between 65% and 85%, a duration of
protection between 10 years and lifelong, and a vaccine
efficacy between 80% and 100% in the base case and best
case, respectively. Additionally, implications for cancer
epidemiology until 2088 are estimated.
Results Compared to screening only, screening plus vacci-
nation of 12-year-old girls (and boys) would result in a
median reduction of 10% (15%) fewer new cancer cases
and 13% (20%) fewer cervical cancer deaths under best
case assumptions over 52 years in the overall female
population. In 2060, female population-based incidence and
mortality would decrease by 27% and 43%, respectively,
when vaccinating girls only and by 37% and 45% when
additionally vaccinating boys. After 2060, a continuous
further decrease in incidence and mortality can be expected
with a maximum of minus 43% and 53%, respectively, in
2088 when vaccinating girls only.
Conclusion Although a constant decrease in cervical cancer
incidence and mortality is to be expected after introducing a
population-wide HPV vaccination program in Austria, the
reduction predicted by this model is lower than expected
from clinical trials. This is due to several factors, such as
low coverage rate and the long time horizon required for
generating the maximum benefit of the vaccination in the
overall population. In the context of limited resources, for
further reducing cervical cancer in Austria, HPV vaccina-
tion programs need to be weighed against other public
health alternatives such as improving screening quality.
Keywords HPV vaccination . Cervical carcinoma
incidence . Cervical carcinoma mortality . Austria
Introduction
It has been demonstrated that infection with certain types of
human papillomavirus (HPV) can cause cervical cancer.
Worldwide, cervical cancer is responsible for 9% of total
cancer-related mortality. However, 80% of the cases
concern the so-called developing countries. In Europe there
are approximately 34,000 new cases of cervical cancer each
year. Around 14,000 women die each year (Ferlay et al.
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2004). In Austria there were 473 new cases of cervical
carcinoma in 2003, and 169 women died from cervical
cancer, representing a 2.8% share of the total cancer
incidence and a 2% share of the total cancer mortality
(Statistik Austria 2007b).
For the past decades the incidence and mortality of
cervical carcinoma have been clearly decreasing in Western
countries, including Austria. This is explained by the
introduction of cytological screening (pap smear). Howev-
er, in comparison with other European countries, the age-
adjusted incidence and mortality rates are high in Austria
(Ferlay et al. 2004). Finland is the European country with
the lowest age-adjusted incidence and mortality rate:
Compared to Austria, in 2002, 6.6 fewer women per
100,000 had developed the disease in Finland than in
Austria, and 2.3 fewer women per 100,000 died from it
(Ferlay et al. 2004). Overall, in Austria screening is
opportunistic rather than organised. Potential for improve-
ment exists in terms of screening attendance rates,
particularly among women from underprivileged groups,
and in terms of screening quality. Although screening is
publicly financed, available data showed an annual screen-
ing participation rate of only 30% in 2005. Participation
decreases with increasing age (Hauptverband der österrei-
chischen Sozialversicherungsträger 2007).
In addition to successful screening programs, the
possibility of immunization against high-risk virus geno-
types has recently been introduced. Both of the two
available HPV vaccines prevent infection from 2 out of
15 identified high-risk HPV genotypes (16 and 18, detected
in about 70% of cancer cases); one additionally protects
against two low-risk types (6 and 11) that are related to
further diseases such as genital warts. As has been shown in
systematic literature reviews, the vaccines have shown high
efficacy in preventing HPV-type-specific infections and
precancerous lesions in clinical studies, the latter being
surrogate parameters for cervical carcinoma (National
Board of Health and Danish Centre for Health Technology
Assessement 2007; Nielsen et al. 2007; Thiry et al. 2007).
There is hope that through vaccination the number of new
cervical cancers will decrease substantially. However,
several important questions remain, such as duration of
protection, overall reduction of cervical cancer regardless of
HPV-type or possible changes in the virus dynamics.
In order to support informed decision making about
whether to recommend (and finance) HPV vaccination
publicly, epidemiological models that aim at long-term
predictions of cervical cancer morbidity and mortality for
various prevention program alternatives are a useful tool.
They have been developed for several countries, often in
combination with an economic evaluation (Kulasingam and
Myers 2003; Sanders and Taira 2003; Goldie et al. 2004,
2007; Taira et al. 2004; Barnabas and Garnett 2005; Garnett
et al. 2006; Brisson et al. 2007; Elbasha et al. 2007; French
et al. 2007; Insinga et al. 2007; Kohli et al. 2007; National
Board of Health and Danish Centre for Health Technology
Assessement 2007; Neilson and Freiesleben de Blasio 2007;
Thiry et al. 2007; Bergeron et al. 2008; Dasbach et al. 2008;
Jit et al. 2008; Kim and Goldie 2008; Kulasingam et al.
2008). However, for producing reliable results, country-
specific models are required that take into account country-
specific features such as screening policy, epidemiology of
the disease under evaluation and HPV prevalence.
Furthermore, many of the published studies focus on
cost-effectiveness results without presenting population-
based epidemiological predictions, or they analyze health
benefits for a single vaccinated cohort only. However, from
a public health perspective as well as from a decision-
maker’s view, it is equally relevant how cancer epidemiol-
ogy may change population-wide for a defined time horizon
after introducing a vaccination program. In the following
article we aim at addressing this question. We present the
results of an epidemiological long-term prognosis for
cervical carcinoma in Austria for a specified time period
assuming different prevention strategies.
Method
Prevention strategies
We analyzed three different prevention strategies: (1) ‘screen-
ing only’ (the current standard treatment); (2) vaccination of
12-year-old girls in addition to screening (HPV F); (3)
vaccination of 12-year-old girls and boys in addition to
screening (HPV F+M). The outcome parameters of interest
were cervical carcinoma incidence and mortality. The time
horizon in the base case analysis was 52 years (from 2008 to
2060). In an additional analysis we extrapolated the results to
the year 2088.
Dynamic model structure
To predict long-term effects, a dynamic compartmental
model developed and applied in the UK and in Norway
(Neilson and Freiesleben de Blasio 2007) was adapted and
validated for Austria. Although the complexity of a
dynamic model limits transparency, this type of model
was chosen to account for herd immunity and to demon-
strate the health effect for women from vaccinating boys.
The model follows a population through HPV infection,
chronic cervical infection and cervix cancer development
based on the natural history of cervical carcinogenesis. The
model simulates HPV transmission, the occurrence of
precancerous lesions (CIN) and the development of cervical
carcinoma (see Table 1 in the next section for progression
4 J Public Health (2010) 18:3–13
Table 1 Model parameters for the dynamic model
Parameter Valuea Source
Natural history of disease
Progression to chronic infection
(type 16, type 18, type other)
0.1;0.085; 0.085 (Goldie et al. 2004; Kim et al. 2007) and references there
Recovery from transient infection
(type 16, type 18, type other)
0.9; 1.3; 1.9 Initial estimates based on (Ho et al. 1998; Muñoz et al. 2004b)
Progression by stage (cin1, cin2,
cin3, cis, ccI, ccII,ccIII, ccIV)
1.7; 0.03; 0.045; 0.15; 0.18;
0.20; 0.20
(Goldie et al. 2004; Kim et al. 2007) and references there
Regression by stage (cin1, cin2, cin3) 0.37; 0.1; 0.04 (Goldie et al. 2004; Kim et al. 2007) and references there
Relative regression (Kim et al. 2007)
cin1 to normal 1.0
cin2 to (cin1, normal) 0.7; 0.3
cin3 (to cin2, cin1, normal) 0.7; 0.15; 0.15
Age-specific progression rate 0.175; 0.6; 0.9; 0.9; 0.9; 1.2 Fitted to Austrian data (Hackl 2007)
Recovery from cancer by stage
(cis, ccI, ccII, ccIII, cIV)
0.35; 0.25; 0.2; 0.1; 0.1 Initial estimates based on Norwegian data; subsequently
fitted to Austrian data (Hackl 2007)
Death rate from CC by stage
(cis, ccI, ccII, ccIII, cIV)
0.05; 0.2; 0.5; 0.85; 1.0 Initial estimates based on Norwegian data; subsequently
fitted to Austrian data (Hackl 2007)
Fraction of slow progressors
(type 16; type 18; type other)
0.96; 0.945; 0.985 Assumption
Relative type-specific progression
(type 16; type 18; type other)
1.0; 1.05; 0.8 Fitted to model
Hysterectomies by age 5e–4; 5e–4; 5e–4; 5e–4;
5e–4; 5e–4
UK data from Geoff Garnett
Age group 1–6
Loss of natural immunity 0.05 Assumption
Transmission rate 0.6; 0.1; 0.3 Fitted to model; initial estimates from Geoff Garnett
(Type 16; type 18; type other)
Type-specific incidence of cervical cancer
(type 16; type 18; type other)
0.55427; 0.15376; 0.29197 (Muñoz et al. 2004a)
Relative type-specific precancerous lesions
(CIN 2/3)
58–59%; 41–42% (Roberts et al. 2006)
(Type 16 + 18: type other)
Screening
Fraction of women screened Base case 0.3 Austrian data (Hauptverband der österreichischen
Sozialversicherungsträger 2007)
Period of implementation 1989–1992 Austrian data (Vutuc et al. 1999)
Relative screening rate by age group 0.96; 1.44; 1.32; 1.13;
0.95; 0.64
Austrian data (Hauptverband der österreichischen
Sozialversicherungsträger 2007)
Sensitivity by stage of pathogenesis (cin1;
cin2; cin3; cis; ccI-IV)
0.50; 0.63; 0.64; 1.0; 1.0 (Coste et al. 2003)
Relative screening rate by sexual
activity and vaccination
(low, medium, high, vaccination)
0.5; 0.5; 0.5; 0.5 Assumption
Vaccination
Efficacy Base case 0.90
Coverage Base case 0.65
(0.5–0.85)
Austrian data (Bundesministerium für Gesundheit Familie
und Jugend (BMGFJ) 2007)
Screening rate of vaccinated women 0.3 Austrian data (Hauptverband der österreichischen
Sozialversicherungsträger 2007)
Waning efficacy/duration of protection Base case
0.0118/10 years
Assumption
Susceptibility of vaccines (type 16;
type 18; type other)
1.0; 1.0; 0.0 (Nielsen et al. 2007)
Sexual behavior
Fraction of activity groups
(low; medium; high)
0.869; 0.125; 0.006 Guided by National Survey of Sexual Attitudes and
Lifestyles II (UK, 2000) and survey of sexual behavior
in Norway, 2002
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rates). Figure 1 presents the model structure and the way it
reflects the natural history of disease.
The model consists of a set of coupled differential
equations that are updated on a weekly basis; the new
compartment sizes are estimated using a fourth-order
Runge-Kutta method. The first 100 years are run without
intervention to let the model reach dynamic equilibrium.
The initial population is assumed equal to the current
Austrian population with a flat age structure. The birth rate
is constant, and no immigration or emigration is considered
during the simulation period. The model divides individuals
into mutually exclusive compartments based on their values
of state parameters. Annual cohorts up to the age of sexual
debut (assumed at the age of 15) are simulated allowing for
age-specific vaccination. In the current analysis vaccination
is at the age of 12. Furthermore, the model handles six ‘10-
year age groups’ at risk of infection and cancer up to the
age of 74. This means that outcome predictions are
restricted to persons aged 15 to 74. As a considerable
proportion of cervical carcinoma incidence und mortality
occurs after the age of 74, the model underestimates the
possible benefit of the vaccination after 2060. While the
model in general handles four groups of viral types (HPV
16, HPV 18, HPV 6/11 and ‘other oncogenic types’), the
current analysis focuses on targeting the high-risk types 16
and 18 only. In the model there are three vaccine statuses:
‘unvaccinated,’ ‘protected’ and ‘vaccinated with loss of
protection.’ Virus transmission is modeled through sexual
mixing, which is divided into three activity classes with
low, medium or high sexual activity defined by the changes
in partnerships per year (see Table 1 for details). Mixing
between individuals depends on their age and activity class.
The resulting number of sexual acts per partnership is
included into the transmission dynamic.
Persons who recover from infection develop type-
specific natural immunity, which is lost at a constant rate
within a given time period. During this time span persons
are, however, susceptible to other HPV types.
Infection can result in precancerous lesions that can
finally lead to invasive cancer. On the other hand,
regression from more severe to less severe stages of
precancerous lesions is possible. Table 1 shows the rates
for progression and regression applied.
Input parameters
Table 1 demonstrates the values for all the input parameters
used in the model as well as the data sources. The values
for the input parameters are either based on published
Table 1 (continued)
Parameter Valuea Source
Relative activity (high; medium; low) 37.0; 8.5; 1.0 Guided by National Survey of Sexual Attitudes and
Lifestyles II (UK, 2000) and survey of sexual behavior
in Norway, 2002
Activity by age Guided by National Survey of Sexual Attitudes and
Lifestyles II (UK, 2000) and survey of sexual behavior
in Norway, 2002
(Age group 1–6) 6.0; 3.0; 2.0; 1.5;
1.0; 0.8
Acts per partnership Guided by National Survey of Sexual Attitudes and
Lifestyles II (UK, 2000) and survey of sexual behavior
in Norway, 2002
High-high; high-med; high-low 2; 12; 104
Med-med, med-low 12; 104
Low-low 104
Average partner change rate 0.8 Guided by National Survey of Sexual Attitudes and
Lifestyles II (UK, 2000) and survey of sexual behavior
in Norway, 2002
a: Rates unless stated otherwise; ccI: cervical carcinoma stage I; cin: cervical intraepithelial neoplasia; cis: carcinoma in situ
Model structure
susceptible
Transient infection
CIN-1
CIN-2
CIN-3
Cancer stage 1
Cancer stage 2
Cancer stage 3
death
Cancer stage 4
recovered
(susceptible to other
types)
slow
fast
Fig. 1 Model structure for the natural history of disease. CIN:
Cervical intraepithelial neoplasia
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literature or on Austria-specific data. For some currently
unknown parameters such as duration of protection, we had to
make assumptions that were varied in sensitivity analysis.
We used Austria-specific screening data that show an
annual screening coverage of around 30%. Yet, as men-
tioned above, participation varies highly depending on the
age group, with older women showing a particularly low
attendance. This was acknowledged in the age-specific
screening parameters. It was assumed that screening
remains unchanged in both vaccinated and unvaccinated
women.
Furthermore, vaccine efficacy in the base case was 90%
against HPV-type-specific infection (based on clinical trial
data). Vaccination coverage for a three-dose vaccination in
12 year olds was assumed to be 65%. This is based on the
average experience from other publicly financed vaccina-
tion programs in Austria where a coverage of only 50% in
school-based publicly funded vaccination programs and of
85% in public vaccination programs for newborns was
shown [Bundesministerium für Gesundheit Familie und
Jugend (BMGFJ) 2007]. Finally, because duration of
vaccine protection is unknown, we assumed waning
vaccine efficacy, and a booster vaccination was imple-
mented after 10 years in the base case (see Table 1 for
details): During a 10-year interval the model assumes that
~11% of the women who were vaccinated and have gained
immunity have lost it again. This value grows with time, so
that 50 years after the initial vaccination ~55% of the
women who acquired immunity through vaccination are
still protected. When a booster vaccination is applied, the
waning process is assumed similar to the one described
above. However, as the model program works with age
groups and therefore does not distinguish between individ-
ual ages within groups, for example, a person aged 15 and
one aged 24, we had to ‘distribute’ the booster among the
entire age group. Assuming that HPV prevalence declines
with age, the effects from the booster will be on the
optimistic side. Overall, parameters and assumptions in the
base case are conservative. They were, however, varied in
the sensitivity analysis.
Model results were used for calculating population-wide
changes in epidemiology by applying data on demography
predictions from Austria (Statistik Austria 2007a).
Validation
For model calibration, the output of the model was fitted to
the age-specific cervical carcinoma incidence and mortality
data from Austria (Hackl 2007). For calibrating the
incidence of type-specific high-grade lesions and cervical
carcinomas, international data were used (Muñoz et al.
2004a; Roberts et al. 2006) (see Table 1). In terms of
validity, we evaluated the predictive validity of the model
by comparing the model results with observed age-specific
and overall Austrian cervical cancer incidence and mortal-
ity data for the years 2001 to 2006.
Sensitivity analysis
To test for uncertainty all key assumptions from the base
case were varied in various one-way sensitivity analyses.
We modified vaccination coverage between 50% and 85%,
and we assumed different durations of protection up to
lifelong protection. Moreover, vaccine efficacy in terms of
protection from persistent infections was varied between
80% and 100%. Finally, we conducted a multivariate
sensitivity analysis where we defined a best case scenario
(100% efficacy, no waning, 85% vaccination coverage) and
ran the model under these assumptions for either vaccinat-
ing girls only or vaccinating girls and boys.
Results
Model validity
Model outputs for cervical carcinoma incidence and
mortality are in accordance with Austrian epidemiological
data. Incidence and mortality rates between 2001 and 2006
in the model do not differ more than 15% from the actual
rates in Austria. If at all, the model slightly overestimates
the rates. However, as Austrian cervical carcinoma epide-
miological data seem to slightly underestimate the true
burden of the disease, this in fact supports external validity
of the model outputs. Figure 2 demonstrates the validation
results for observed total cervical carcinoma incidence and
mortality for those years where data were available
compared with the model results. Similar to overall
incidence and mortality, age-specific incidence and mortal-
ity predicted by the model are consistent with observed
data.
Epidemiological impact of different HPV vaccination
strategies
Tables 2 and 3 show the results for cervical carcinoma
incidence and mortality predictions in Austria until 2060
for women aged 15 to 74 for the different prevention
strategies and for the base case as well as for the best case
scenarios.
Compared to screening only, vaccination of 12-year-old
girls would result in a constant reduction of cervical
carcinoma incidence and mortality over the next 52 years.
Due to the natural history of cervical carcinoma develop-
ment out of precancerous lesions, reduction starts to
become visible after 20 years. In the year 2060, compared
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to screening only, minus 23% incidence cases and minus
27% cervical carcinoma deaths would have to be expected
under the base case assumptions (coverage rate of 65%,
90% efficacy against persistent HPV 16/18 infection and
waning efficacy including a booster in year 10). On
average, incidence and mortality would be reduced by 9%
and 11%, respectively, over 52 years. This equals roughly
2,240 fewer new cancer cases and 770 fewer deaths
compared to screening only. However, 22,000 women in
Austria would still develop cervical cancer and about 6,000
would die over 52 years.
Vaccinating girls and boys increases the reduction of
incidence and mortality to minus 33% and minus 39% in
2060, which corresponds to 14% fewer new cases and 18%
fewer deaths on average over 52 years. In absolute numbers
3,440 new cases and 1,200 deaths could be prevented by the
vaccination program compared to screening only, while
20,800 women would still develop cervical cancer, and
5,500 would die despite introducing the vaccination program.
Figure 3 demonstrates the results of the one-way and
multivariate sensitivity analyses for the case of vaccinating
girls only. In a best case scenario (85% coverage, 100%
vaccine efficacy, life-long protection) reductions of inci-
dence and mortality would increase further. When vacci-
nating girls only, in 2060 27% fewer new cancer cases and
32% fewer cancer deaths compared to screening only can
be expected. Vaccination of girls and boys under best case
assumptions increases reductions further. While over
52 years in the ‘HPV F-scenario’ 2,500 (10%) new cases
and 870 (13%) deaths would be prevented, compared to
screening only, in the ‘HPV F + M-scheme’ the number of
prevented new cases and deaths rises to almost 3,700 (15%)
and 1,330 (20%), respectively (figures not shown). This
corresponds to an overall reduction in incidence rate until
2060 of 1.4 per 100,000 women when vaccinating girls and
minus 2 per 100,000 women when vaccinating girls and
boys. Accordingly, reduction in mortality rates would be
expected at minus 0.5 per 100,000 women when vaccinat-
ing girls only and minus 0.7 per 100,000 women when
additionally vaccinating boys.
Furthermore, the model demonstrates that increasing the
coverage rate to 85%while leaving all other assumptions from
the base case (booster in year ten, 90% vaccine efficacy)
unchanged is almost as effective as the best case scenario
where, in addition to a 85% coverage rate, lifelong protection
and a slightly higher vaccine efficacy were assumed.
As may be anticipated, more pessimistic scenarios, such
as reducing the coverage rate to below 60% or assuming
waning vaccine efficacy without a booster, result in lower
health benefits (see Fig. 3). For example, in the case of
waning efficacy without giving a booster, the model
predicts a reduction of 17% and 19% in cervical cancer
incidence and mortality, respectively, in 2060 when
vaccinating girls only. Over 52 years 700 more women
would develop cancer and 240 more women would die of
cervical cancer than under base case assumptions where a
booster is assumed.
Since generating the maximum benefit of HPV vaccina-
tion will require a considerably longer time span than
52 years, the results have been further extrapolated to the
year 2088. Figure 4 shows the expected reduction in
incidence and mortality compared to screening only for
Austria given all other circumstances remain unchanged.
As the figure demonstrates, further health gains can be
expected in the long run. However, even in 2088 (80 years
after introduction of the vaccination program) reduction in
population-wide incidence does not exceed minus 43%, and
mortality reduction could at best be expected at minus 53%.
Validation results for cervical carcinoma incidence and mortality
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Discussion
Results from clinical HPV vaccination trials have shown a
very favorable vaccine efficacy with respect to preventing
HPV 16/18 infections and HPV 16/18 precancerous lesions.
Since these two genotypes have been observed in at least
70% of cervical carcinomas, a reduction of cervical cancer
close to 70% has been announced by the vaccine devel-
opers. In contrast to models that have analyzed long-term
effects in vaccinated cohorts only, the strength of our
approach is that it provides information on the overall
public health impact with respect to cervical cancer within a
defined time period, which is likely to be of relevance for
decision makers. The model results for the Austrian case
show that viewed from an overall epidemiological perspec-
tive, reduction in cervical cancer incidence and mortality—
at least within the next 50 years—lies considerably below
the expected magnitude.
This can be explained by several reasons. Firstly, even in
the best case, vaccination coverage rate and vaccine
efficacy will be below 100% in a real-life situation. This
hinders virus elimination, which is generally difficult to
achieve in sexually transmitted viruses (Garnett 2005).
Secondly, it takes a long time to benefit from the
vaccination with respect to cervical cancer because of the
long time span the cancer takes to develop. Hence, in
50 years time many women who would have been
vaccinated by then would not have had ‘the chance’ to
accrue the benefits. The main reason, however, is that
introducing a vaccination program, even if population-
wide, means that there will still be many unvaccinated
(older) women whose risk of developing cancer remains
unchanged provided that the current screening praxis is
being continued. In other words, a large proportion of the
demonstrated cancer (mortality) cases will occur due to the
HPV infections in women who are older than 12 in 2008
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and who would not be vaccinated. Part of these cases may
be reduced by introducing a catch-up program, which has
shown favorable results in other studies (e.g., the National
Board of Health and Danish Centre for Health Technology
Assessement 2007). As this alternative was not considered by
the Austrian decision makers, it was not addressed in the
model but may be interesting to focus on in further research.
As has been shown in the sensitivity analysis, under the
assumption of an 85% coverage rate (+ booster in year 10
and 90% vaccine efficacy), reductions of incidence and
mortality are almost as high as under best case assumptions
where, in addition to the former, lifelong duration of
protection and a slightly higher vaccine efficacy have been
assumed. This can be explained by several factors. Firstly,
the coverage rate seems to be more influential than other
factors such as vaccine efficacy. Secondly, as has been
mentioned earlier, the booster in the ‘85% coverage
scenario’ tends to slightly overestimate the health benefits
because of the model characteristics. In other words, the
booster more than compensates for the assumed loss of
efficacy, and the effects are gained early in time. As a
consequence, under the assumption of lifelong protection,
health gains with respect to reduced mortality are slightly
lower than in the ‘85% coverage scenario.’ In the long run,
however, the difference diminishes.
Our results differ from other studies that have shown
more favorable effects (Goldie et al. 2004; Barnabas and
Garnett 2005; Elbasha et al. 2007; French et al. 2007;
Insinga et al. 2007; Kohli et al. 2007; Dasbach et al. 2008).
This is firstly due to the different research question in our
study, which addresses population-wide benefits for a given
time period rather than health effects for vaccinated cohorts.
Furthermore, some studies addressed the epidemiological
impact for HPV 16/18-related carcinomas only (Barnabas
and Garnett 2005; French et al. 2007) or evaluated
epidemiological changes for a 100-year time frame, while
we addressed the impact on total cancer incidence and
mortality for a maximum of 80 years. Another reason for
differences in results is that the situation in Austria
generally differs from other countries, especially in terms
of screening quality and baseline epidemiology. For
instance, in the scenario ‘vaccination of 12-year-old girls,’
the low screening participation rate (in unvaccinated
women) will result in higher total incidence and mortality
rates in Austria than in countries with higher screening
participation. This may for example be one reason that the
reduction in cervical cancer in the Elbasha et al. (2007)
base case is higher than in ours. Furthermore, in most of the
studies assumptions concerning vaccination have been
more optimistic than in ours, particularly with respect to
vaccination coverage, vaccine efficacy and duration of
protection (e.g. Elbasha et al. 2007), while we chose a
conservative approach. Finally, in contrast to other studies
(Goldie et al. 2004; Elbasha et al. 2007), our analysis has
been restricted to invasive cervical carcinoma only, thus not
demonstrating the impact of vaccination on precancerous
lesions or on other (rare) HPV-related diseases (such as
vulval cancer).
On the other hand, other studies have also presented less
favorable results when considering less optimistic assump-
tions in sensitivity analyses. For example, Elbasha et al.
(2007) demonstrated a long-term reduction of new cervical
carcinomas of 28% per year when choosing a vaccine
protection of 10 years only compared to 91% reduction in
their most effective strategy. Additionally, studies that
particularly take into account the difficulties of preventing
a sexually transmitted infection (e.g., Hughes et al. 2002)
have also shown less encouraging results.
As has been mentioned in the introduction, further
studies on HPV vaccination exist that focus on economic
evaluation. We do not discuss their results here because we
restricted our paper to epidemiological outputs only.
However, this issue has been addressed in a separate paper
(Zechmeister et al. 2009).
Although the focus on invasive carcinoma only is
justified by its highest burden of disease within the HPV-
related diseases and by the fact that the prevention of
cervical carcinoma has been one of the main arguments
brought forward by the proponents of the vaccination, this
is at the same time the main limitations of the study. Most
importantly, since precancerous lesions contribute substan-
tially to the costs and burden of disease, evaluating them as
a separate outcome parameter would make additional health
benefits of the vaccine visible and benefits observable
earlier. On the other hand, some factors that may have a
contrary effect have also not been taken into account in the
model. These are, for example, the immigration of
unvaccinated persons, possible changes in virus dynamics
or in the risk behavior of vaccinated people. For instance,
we do not know whether the behavior of vaccinated women
in terms of screening and safer sex will change and in
which way this change will occur.
Further limitations of the study are related to data
restrictions. Although Austrian data have been used to
populate the model wherever possible, such data were not
available for some parameters such as the sexual activity.
Thus, they were based on UK and Norwegian survey data
that were used in the original model. Although these
countries have a cultural context similar to Austria, we do
not know how exactly they reflect the sexual behavior of
Austrians.
Finally, the predictions for the period after 2060 face
increased uncertainty since, firstly, demographic data were
not available until 2088, and predictions for such a long
time horizon generally have to be treated with caution.
Secondly, as mentioned in the methods section, the model
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only predicts results for women aged 15 to 74. In the
prediction up to 2088, an increasing proportion of women
will be older than 74 years. Potential cases avoided in these
women are not shown by the model, and therefore the
model underestimates the benefits in the extended scenario.
The study has raised some important issues for further
research. For example, it is likely that due to the reduction
in the incidence of precancerous lesions, changes in
screening policy will be required. As has been done by
others (e.g., Kulasingam and Myers 2003; Goldie et al.
2004), modeling could as well be used to analyze the
impact of different screening strategies. Not least, more
detailed sensitivity analysis will be required in future
research for further uncertain parameters such as natural
immunity or sexual activity.
Conclusion
The study has demonstrated that a population-wide vacci-
nation program against HPV 16/18 would in the long run
result in a further decrease of cervical carcinomas in
Austria. However, due to the nature of the disease and the
apparent difficulty of high vaccination coverage in Austria,
after 50 years of vaccination, the health gains in terms of
overall population health will be far from the expected
maximum benefit.
In the context of increasing budget constraints, intro-
ducing a publicly financed HPV vaccination program needs
to be weighed against other possible (cheaper) alternatives,
the more so as the epidemiologic relevance of cervical
cancer is low in Austria compared to other types of cancer
in women (e.g., breast cancer, lung cancer). Since there is
considerable room for improvement in screening quality, a
reduction of cervical cancer may also be achieved by a
better organized screening system at lower costs, leaving
more resources for other preventive measure for more
pressing health problems. This needs to be addressed in
further research, particularly in economic evaluations.
However, it needs to be born in mind that screening is a
suboptimal secondary prevention measure in contrast to
primary prevention with vaccination.
As a number of new vaccines for increasingly less
virulent or prevalent diseases are currently in development
and health-care budgets come ever more under pressure,
more thoughts need to be spent on how to support rational
vaccination policy that systematically takes into account
epidemiological, health economic, organizational and equi-
ty criteria (Piso and Wild 2008).
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